Emflaza
Active Ingredient(s): DeflazacortFDA Approved: * February 9, 2017
Pharm Company: * MARATHON PHARMACEUTICALS LLC
Category: Anti-Inflammatory
* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".
Emflaza Overview
Deflazacort (trade name Emflaza or Calcort among others) is a glucocorticoid used as an anti-inflammatory and immunosuppressant. Contents 1 Medical uses 2 Adverse effects 3 Pharmacology 3.1 Mechanism of action 3.2 Relative potency 4 History in the US 5 Clinical Trials 6 Commercial Aspect 7 Society and Culture 7.1 Patents 8 References Medical uses The manufacturer lists the following uses for deflazacort:[1] Acute interstitial nephritis Anaphylaxis Asthma Autoi...
Read more Emflaza DetailsDetails May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Deflazacort
Recent Emflaza Forums:
Be the first to start a discussion about this drug.Possible Dosages for this and Related Drugs:
Deflazacort
- Suspension: 22.75mg/ml
- Tablet: 18mg, 30mg, 36mg, 6mg
NDC Database Records for Emflaza: (10 results)
Sorted by National Drug Code- 42998-501 Emflaza 6 mg Oral Tablet by Marathon Pharmaceuticals, LLC
- 42998-502 Emflaza 18 mg Oral Tablet by Marathon Pharmaceuticals, LLC
- 42998-503 Emflaza 30 mg Oral Tablet by Marathon Pharmaceuticals, LLC
- 42998-504 Emflaza 36 mg Oral Tablet by Marathon Pharmaceuticals, LLC
- 42998-505 Emflaza 22.75 mg/ml Oral Suspension by Marathon Pharmaceuticals, LLC
- 52856-501 Emflaza 6 mg Oral Tablet by Ptc Therapeutics, Inc.
- 52856-502 Emflaza 18 mg Oral Tablet by Ptc Therapeutics, Inc.
- 52856-503 Emflaza 30 mg Oral Tablet by Ptc Therapeutics, Inc.
- 52856-504 Emflaza 36 mg Oral Tablet by Ptc Therapeutics, Inc.
- 52856-505 Emflaza 22.75 mg/ml Oral Suspension by Ptc Therapeutics, Inc.